Better Health for All

GENFIT's core business is dedicated to improving the health and quality of life for patients with rare and severe liver diseases, including Acute-on-Chronic Liver Failure (ACLF) and Primary Biliary Cholangitis (PBC). Their lead molecule, elafibranor (Iqirvo®), developed to Phase 3, has received approvals from the FDA, EMA, and MHRA for PBC.

The company provides free access to innovative drugs in clinical trials, covering all medical expenses for participants, and focuses on diseases with few or no therapeutic solutions, supporting vulnerable patients. GENFIT has not been involved in any legal proceedings related to safety, and clinical trials are conducted in strict compliance with ethical guidelines, including the Declaration of Helsinki and ICH recommendations. The company publishes an Extra-Financial Performance Report annually since 2021 and provides detailed information through various channels. In 2023, Ipsen invested €619 million in R&D, representing 20% of total sales, which includes the licensed elafibranor from GENFIT. GENFIT's direct environmental footprint is limited, and it is committed to minimizing its impact. GENFIT supports local initiatives like PAQTE and French Tech Lille, and in 2024, distributed its apprenticeship tax among four local organizations. The company offers employees an annual flu vaccination campaign, with 55 employees vaccinated in 2024, and provides comprehensive health insurance plans. GENFIT collects and processes personal data in clinical trials in accordance with GDPR, using pseudonymized data and implementing various policies and technical tools for data protection. The company supported Ukrainian displaced persons in 2022 through employee collections. GENFIT produces educational content on ACLF and partners with doctors and patients to foster an inclusive approach to liver disease awareness.

Fair Trade & Ethical Sourcing

The provided articles do not contain any specific data points or information relevant to GENFIT S.A.'s fair trade and ethical sourcing practices, supply chain audits, child/forced labor incidents, traceability, remediation speed, ethical clause coverage, materials risk, or supplier diversity spend.

Therefore, no KPIs can be scored based on the evidence provided.

Honest & Fair Business

GENFIT S.A. has a Code of Business Conduct & Ethics, effective January 2024, outlining ethical and legal standards for employees

, . The company has a confidential and anonymous financial concern hotline for complaints about accounting, internal accounting controls, or auditing matters, as required by the SEC . Six out of nine board members are considered independent . The company's Code of Business Conduct & Ethics details prohibitions against bribery, kickbacks, improper payments, and insider trading, referencing French and US laws (including the FCPA) . The company publishes an annual ESG report with third-party verification . These factors support a score of 10. There is no evidence of regulatory fines or controversies. However, there is no quantitative data available on governance metrics , .

Kind to Animals

GENFIT applies the 3Rs principle (Reduce, Replace, Refine) in animal experimentation and has an internal Animal Experimentation Ethics Committee (CEMEA/CARE) registered since October 11, 2012, with the French National Committee for Animal Experimentation.

The company adheres to the European Directive 2010/63EU on animal experimentation. GENFIT is developing an innovative organoids program as an intermediary model between cell lines cultures and animal models. Annually, the Ethics Committees report to the Ministry on the number of animals used and the severity of procedures. GENFIT conducts regular audits for its subcontractors to ensure rigorous surveillance of all outsourced activities. The company is part of the “Responsibility and Reputation” commission of the LEEM (French Pharmaceutical Companies Association) and its Ethics Committee promotes the national charter on animal experimentation.

No War, No Weapons

The provided articles describe GENFIT S.A. as a biopharmaceutical company focused on the discovery and development of therapeutic solutions for metabolic and liver diseases.

The company's research and development pipeline is detailed, including programs for Acute-on-Chronic Liver Failure, Hepatic Encephalopathy, Cholangiocarcinoma, and Urea Cycle Disorders. While one article mentions a commitment to Corporate Social Responsibility, none of the articles contain any specific, quantitative, or qualitative data related to arms manufacturing, military contracts, dual-use technologies, sales to sanctioned regimes, peacebuilding investments, or any other metrics relevant to the 'No War, No Weapons' ethical value. Therefore, no KPIs can be scored based on the provided evidence.

Planet-Friendly Business

GENFIT's total Scope 1, 2, and 3 greenhouse gas emissions for 2024 were 1,463 tCO2e, an increase from 1,388 tCO2e in 2023 and 1,367 tCO2e in 2022.

The company acknowledges its emissions are relatively limited. A biodegradability study was initiated for VS-01 and NTZ, its most advanced drug candidates. Carbon offsetting for business travel uses projects certified with GOLD Standard, VCS from VERRA, or CCB standard from CCBA. GENFIT's new purchasing policy includes a contractual clause encouraging suppliers to disclose information for Scope 3 reporting, and it drew up a global partner code of conduct and general CSR clauses for key business partners in 2024. The company has adapted green spaces to better respect biodiversity, including setting up a 'no-mow zone' and stopping the use of plant-protection products. No refrigerant leaks were recorded in 2024, 2021, or 2020. A building energy audit was conducted in 2024. GENFIT formalizes its reporting following ISO26000, SASB, GRI, and SDGs standards, and its website is designed according to eco-design principles. The company replaced plastic water bottles with returnable glass bottles, saving 4 tonnes of CO2 in 2024. In 2020, during a workforce restructuring, an HR service provider was appointed to support employees, and a 24/7 psychological support unit was set up.

Safe & Smart Tech

The company's privacy policy states that data is collected only as necessary, with a retention period of 13 months.

It also outlines user rights including information, correction, deletion, restricted processing, data portability, and complaint filing. The policy references compliance with GDPR and other relevant regulations.